1. Discuss key practice-changing data or “hot topics” in gynecologic oncology from ASCO 2020

2. Summarize take home points and future directions

3. Discuss the new immunotherapy combination FDA approvals in advanced NSCLC

4. Explain the importance of NGS testing in NSCLC in light of promising targeted therapy approaches in early stage and advanced NSCLC

5. Define the role of immunotherapy combinations in SCLC

Attendee link to WebEx event


Session date: 
09/02/2020 - 8:00am to 9:00am CDT
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Ticiana Leal
Dr. Elisavet Paplomata